[{"id":"6b3fd358-0eaf-4894-b112-d5bec4021ece","acronym":"","url":"https://clinicaltrials.gov/study/NCT05877430","created_at":"2023-05-26T15:07:03.626Z","updated_at":"2024-07-02T16:35:25.993Z","phase":"Phase 1/2","brief_title":"Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer","source_id_and_acronym":"NCT05877430","lead_sponsor":"CJ Bioscience, Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" PD-L1 expression • BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • CJRB-101"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 09/11/2023","start_date":" 09/11/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2023-12-18"}]